X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (182) 182
index medicus (178) 178
oncology (143) 143
male (110) 110
cancer (107) 107
urology & nephrology (82) 82
chemotherapy (79) 79
aged (70) 70
middle aged (66) 66
female (60) 60
bladder cancer (59) 59
urology (58) 58
care and treatment (56) 56
antineoplastic agents - therapeutic use (50) 50
prostate cancer (47) 47
treatment outcome (46) 46
cisplatin (45) 45
aged, 80 and over (43) 43
metastasis (41) 41
antineoplastic combined chemotherapy protocols - therapeutic use (40) 40
survival (38) 38
hematology, oncology and palliative medicine (34) 34
urinary bladder neoplasms - drug therapy (34) 34
article (32) 32
carcinoma (32) 32
urothelial carcinoma (31) 31
medical colleges (30) 30
neoplasm metastasis (30) 30
prognosis (30) 30
analysis (29) 29
adult (28) 28
clinical trials (28) 28
research (28) 28
transitional-cell carcinoma (27) 27
urologic neoplasms - drug therapy (27) 27
carcinoma, transitional cell - drug therapy (25) 25
cisplatin - administration & dosage (25) 25
urothelial cancer (25) 25
abridged index medicus (24) 24
disease-free survival (24) 24
neoadjuvant chemotherapy (24) 24
phase-ii trial (24) 24
retrospective studies (24) 24
gemcitabine (23) 23
therapy (23) 23
urinary bladder neoplasms - pathology (23) 23
methotrexate (22) 22
neoplasms - drug therapy (22) 22
tumors (22) 22
antineoplastic agents (21) 21
docetaxel (21) 21
prostatic neoplasms - drug therapy (21) 21
randomized controlled trials as topic (20) 20
antimitotic agents (19) 19
cystectomy (19) 19
drug therapy (19) 19
radical cystectomy (19) 19
survival analysis (19) 19
antineoplastic agents - adverse effects (18) 18
immunotherapy (18) 18
neoplasm staging (18) 18
urologic neoplasms - pathology (18) 18
bladder-cancer (17) 17
clinical trials as topic (17) 17
vinblastine (17) 17
metastatic (16) 16
patient outcomes (16) 16
health aspects (15) 15
paclitaxel (15) 15
prostatic neoplasms - pathology (15) 15
urinary bladder neoplasms - mortality (15) 15
antineoplastic agents - administration & dosage (14) 14
cisplatin - therapeutic use (14) 14
clinical trials, phase ii as topic (14) 14
doxorubicin (14) 14
medicine & public health (14) 14
neoplasm invasiveness (14) 14
phase-iii trial (14) 14
risk (14) 14
taxoids - administration & dosage (14) 14
urinary bladder neoplasms - therapy (14) 14
urothelium - pathology (14) 14
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
deoxycytidine - analogs & derivatives (13) 13
survival rate (13) 13
animals (12) 12
cancer therapies (12) 12
cell lung-cancer (12) 12
cooperative-oncology-group (12) 12
expression (12) 12
meta-analysis (12) 12
multicenter (12) 12
prostatic neoplasms, castration-resistant - drug therapy (12) 12
prostatic neoplasms, castration-resistant - pathology (12) 12
risk factors (12) 12
trial (12) 12
usage (12) 12
carboplatin (11) 11
cisplatin - adverse effects (11) 11
clinical-trials (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 07/2018, Volume 559, Issue 7714, pp. 1 - 2
The resulting decrease in tumour size is often monitored in the clinic by tracking a decline in the level of a protein called prostate-specific antigen (PSA).... 
Proteins | Androgens | Animals | Medical prognosis | Neutrophils | Gene expression | Cancer therapies | Prostate cancer | Cancer | Tumors
Journal Article
European Urology, ISSN 0302-2838, 07/2019, Volume 76, Issue 1, pp. 82 - 83
Journal Article
European Urology, ISSN 0302-2838, 10/2019, Volume 76, Issue 4, pp. 435 - 436
Journal Article
BJU International, ISSN 1464-4096, 08/2019, Volume 124, Issue 2, pp. 290 - 296
Journal Article
NATURE REVIEWS UROLOGY, ISSN 1759-4812, 02/2018, Volume 15, Issue 2, pp. 71 - U15
Landmark papers published in 2017 have advanced our understanding of the molecular heterogeneity of urothelial cancer, provided insights into the genomic... 
MULTICENTER | PEMBROLIZUMAB | THERAPY | COMPREHENSIVE MOLECULAR CHARACTERIZATION | CISPLATIN-INELIGIBLE PATIENTS | UROLOGY & NEPHROLOGY | METASTATIC UROTHELIAL CARCINOMA | SINGLE-ARM | CANCER | CHEMOTHERAPY | PHASE-2 TRIAL
Journal Article
Journal of Urology, ISSN 0022-5347, 10/2012, Volume 188, Issue 4, p. 1114
Journal Article
Journal of Urology, ISSN 0022-5347, 10/2012, Volume 188, Issue 4, pp. 1114 - 1114
Journal Article
The Journal of Urology, ISSN 0022-5347, 10/2012, Volume 188, Issue 4, pp. 1114 - 1114
Journal Article
The Journal of Urology, ISSN 0022-5347, 10/2012, Volume 188, Issue 4, p. 1114
Journal Article
The Journal of Urology, ISSN 0022-5347, 05/2012, Volume 187, Issue 5, pp. 1554 - 1554
Journal Article
Journal of Urology, ISSN 0022-5347, 05/2012, Volume 187, Issue 5, pp. 1554 - 1554
Journal Article
Journal of Urology, ISSN 0022-5347, 05/2012, Volume 187, Issue 5, p. 1554
Journal Article
JAMA, ISSN 0098-7484, 09/2019, Volume 322, Issue 12, p. 1209
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10031, pp. 1909 - 1920
Journal Article
Journal of Urology, The, ISSN 0022-5347, 2012, Volume 187, Issue 5, pp. 1554 - 1554
Journal Article
Journal of Urology, The, ISSN 0022-5347, 2012, Volume 188, Issue 4, pp. 1114 - 1114
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.